Camzyos (Mavacamten) for Heart disease | MyHeartDiseaseTeam

Connect with others who understand.

sign up Log in
About MyHeartDiseaseTeam
Powered By

Camzyos is approved by the U.S. Food and Drug Administration (FDA) to treat adults with symptomatic New York Heart Association class 2 and 3 obstructive hypertrophic cardiomyopathy (HCM). Camzyos is also known by its drug name, mavacamten.

Camzyos is a cardiac myosin inhibitor. It works by inhibiting the activity of cardiac myosin, a protein that is essential for heart muscle contraction. This helps to reduce heart muscle stiffness and improves blood flow to the heart.

How do I take it?
Camzyos is available in capsule form for oral use. The dose will depend on your overall health and your response to the treatment. Always take this medication exactly as prescribed by your doctor.

Side effects
Common side effects of Camzyos include dizziness and fainting.

Rare but serious side effects may include heart failure. There is also a risk of heart failure due to complications from other medications, so it’s important to discuss all of your medications with your doctor before starting this one. Camzyos may cause fetal harm, so people who could get pregnant are advised to use birth control while taking Camzyos and for four months after the last dose.

For more information about this treatment, visit:

Camzyos — Bristol Myers Squibb

Mavacamten — MedlinePlus

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in